VIDEO: Ibrutinib plus chemoimmunotherapy ‘promising’ for young patients with CLL
Click Here to Manage Email Alerts
Ibrutinib plus fludarabine, cyclophosphamide and rituximab, or FCR, yielded deep responses in younger patients with chronic lymphocytic leukemia over a median follow-up of 40 months.
In general, the regimen showed good tolerability in this younger, fit patient population, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, told Healio of the data presented at the ASH Annual Meeting and Exposition. The long-term follow-up data showed deeper responses over the last couple of years, with a rate of complete remission with bone marrow undetectable measurable residual disease (MRD) of 55%. Also, about 84% of the patients achieved undetectable MRD in the bone marrow, according to Davids.
“These are some of the deepest responses ever observed with a regimen in front-line CLL,” he said. “We think this is a very promising regimen for young, fit patients.”
Importantly, Davids noted that the depth of responses seemed the same regardless of IGHV mutation status.
Collapse
Davids MS, et al. Abstract 640. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Click Here to Manage Email Alerts